Shattuck Labs (STTK) concentration risks

Shattuck Labs' disclosed concentration centers on its pipeline: the company's lead program is SL-325, a potentially first-in-class DR3 blocking antibody built on its DR3 platform. This is a structural characteristic of a clinical-stage biotech rather than a customer or supplier dependency — the company's near-term prospects are tied closely to the clinical advancement of this single lead candidate rather than to any counterparty relationship. No other concentration exposures are disclosed in the available sources, which means SL-325's development trajectory is effectively the dominant factor shaping Shattuck's outlook in this filing. Because the platform is described as potentially first-in-class, the risk here cuts both ways: a positive clinical outcome could be a significant value driver precisely because there is limited direct precedent to benchmark against, while a setback would concentrate its impact given the absence of a broader, more diversified pipeline or revenue base to absorb it. Investors should weigh this single-asset structural concentration as the primary lens for assessing Shattuck's near-term risk and opportunity, since the filing does not point to additional customer, geographic, or supplier exposures that would otherwise diversify that risk.

For the engine’s reasoning on STTK’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.